Madhav Vasanthavada net worth and biography

Madhav Vasanthavada Biography and Net Worth

Insider of Abeona Therapeutics

Prior to Abeona, Dr. Vasanthavada served in commercial leadership roles at Bristol Myers Squibb (BMS) and Celgene, where he led the marketing team in the Global CAR-T Cell Therapy Franchise to launch two autologous cell therapies, Breyanzi® (lisocabtagene maraleucel) and Abecma® (idecabtagene vicleucel), in key worldwide markets. Previously, Dr. Vasanthavada served in a variety of U.S. commercial roles at Bayer in marketing, market access and sales, and was ultimately the brand leader for Xofigo® (radium Ra 223 dichloride). He began his career as a scientist in Novartis R&D where his work led to multiple patents and publications. Dr. Vasanthavada holds a Ph.D. in Pharmaceutical Sciences from the University of Rhode Island, and an M.B.A. from the Harvard Business School.

What is Madhav Vasanthavada's net worth?: The estimated net worth of Madhav Vasanthavada is at least $1.90 million as of January 22nd, 2026. Vasanthavada owns 318,619 shares of Abeona Therapeutics stock worth more than $1,895,783 as of May 4th. This net worth estimate does not reflect any other assets that Vasanthavada may own. Learn More about Madhav Vasanthavada's net worth.
How do I contact Madhav Vasanthavada?: The corporate mailing address for Vasanthavada and other Abeona Therapeutics executives is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. Abeona Therapeutics can also be reached via phone at 214-665-9495 and via email at [email protected]. Learn More on Madhav Vasanthavada's contact information.
Has Madhav Vasanthavada been buying or selling shares of Abeona Therapeutics?: Madhav Vasanthavada has not been actively trading shares of Abeona Therapeutics in the last ninety days. Most recently, Madhav Vasanthavada sold 12,610 shares of the business's stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $5.29, for a transaction totalling $66,706.90. Following the completion of the sale, the insider now directly owns 318,619 shares of the company's stock, valued at $1,685,494.51. Learn More on Madhav Vasanthavada's trading history.
Who are Abeona Therapeutics' active insiders?: Abeona Therapeutics' insider roster includes Leila Alland (Director), Mark Alvino (Director), Michael Amoroso (CEO), Edward Carr (CAO), Faith Charles (Director), Eric Crombez (Director), Brendan O'Malley (SVP), Vishwas Seshadri (CEO), Christine Silverstein (Director), Madhav Vasanthavada (Insider), Joseph Vazzano (CFO), and Todd Wider (Director). Learn More on Abeona Therapeutics' active insiders.
Are insiders buying or selling shares of Abeona Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 527,843 shares worth more than $2,987,597.61. The most recent insider tranaction occured on February, 2nd when Director Leila Alland sold 18,065 shares worth more than $91,950.85. Insiders at Abeona Therapeutics own 5.4% of the company. Learn More about insider trades at Abeona Therapeutics.
Information on this page was last updated on 2/2/2026.

Madhav Vasanthavada Insider Trading History at Abeona Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/22/2026	Sell	12,610	$5.29	$66,706.90	318,619

Madhav Vasanthavada Buying and Selling Activity at Abeona Therapeutics

Abeona Therapeutics Company Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Today's Range

Now: $5.95

$5.42

$6.03

50 Day Range

MA: $4.98

$4.23

$5.63

2 Week Range

Now: $5.95

$4.00

$7.54

Volume

1,845,772 shs

Average Volume

1,190,612 shs

Market Capitalization

$338.44 million

P/E Ratio

5.78

Dividend Yield

N/A

Beta

1.35